In a move aimed at boosting development of its nanopore sequencing technology, Swiss cancer giant Roche (ROG: SIX) has bought out early-stage sequencing expert Stratos Genomics.
The two companies started working together in 2014, after Roche made a strategic investment to support development of single molecule sequencing of DNA fragments.
In the same year, as part of its push into DNA sequencing technology, Roche announced plans to buy California’s Genia Technologies for up to $350 million. The firm was eventually incorporated into the Roche Sequencing Unit.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze